

Anti-CD3 Light Chain Variable Region

| | |
|---|-----|
| GACTTTATGCTTACTCAGCCCCCACTCTGTGTCTGAGTCTCCCGAAAGACAGTCATTATT | 60 |
| D F M L T Q P H S V S E S P G K T V I I | 20 |
| TCTTGACACACTCAGCTCTGGTAACATAGAAAAACAACACTATGTGCACCTGGTACCAGCAAAGG | 120 |
| S C T L S S G N I E N N Y V H W Y Q Q R | 40 |
| CCGGGAAGAGCTCCCACTCGTGATTTTCGATGATGATAAGACCCGGATGGTGTCCCT | 180 |
| P G R A P T L V I F D D D K R P D G V P | 60 |
| GACAGGTTCTCTGGCTCCATTGACAGGCTTCCAACTCAGCCTCCCTGACAAATCAGTGGT | 240 |
| D R F S G S I D R S S N S A S L T I S G | 80 |
| CTGCAAACTGAAGATGAAGCTGACTACTACTGTCACTTCTTATGTTAGTAGTTTAAATGTT | 300 |
| L Q T E D E A D Y Y C H S Y V S S F N V | 100 |
| TTCGGCGGTGGAACAAAGCTCACTGTCCCTT 330 (SEQ ID NO:16) | |
| F G G G T K L T V L 110 (SEQ ID NO:15) | |

Figure 1

Anti-CD3 Heavy Chain Variable Region

| | |
|---|--------------------|
| CAGGTCCAATTGCAGGAGTCTGGGGCGGTTTAGTGACGCTGGAAGGTCCATGAAACTC | 60 |
| Q V Q L Q E S G G L V Q P G R S M K L | 20 |
| TCCTGTGCAGCCTCAGGATTCACTTTCAGTAGCTTCCAAATGGCCTGGGTCCGCCAGGCT | 120 |
| S C A A S G F T F S S F P M A W V R Q A | 40 |
| CCAAAGAAGGTCTGGAGTGGGTCGCAACCATTAGTACTAGTGGTAGAACTTACTAT | 180 |
| P K K G L E W V A T I S T S G G R T Y Y | 60 |
| CGAGACTCCGTGAAGGGCCGATTCACTATCTCCAGAGATAATGGGAAAAGCATCCTATAC | 240 |
| R D S V K G R F T I S R D N G K S I L Y | 80 |
| CTGCAAAATGAATAGTCTGAGGCTGAGGACACGGCCACTTATTACTGTTC AAGATTTCGG | 300 |
| L Q M N S L R S E D T A T Y Y C S R F R | 100 |
| CAGTACAGTGGTGGCTTTGATTACTGGGGCCAAAGGGACCACGGTCACCGTCAGCTCA | 357 (SEQ ID NO:18) |
| Q Y S G G F D Y W G Q G T T V T V S S 119 (SEQ ID NO:17) | |

Figure 2

Aglycosylated Human IgG1 Constant Region

GCCTCCACCAAGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGG
A S T K G P S V F P L A P S S K S T S G
GGCACAGCGGCCCTGGGCTGCCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCG
G T A A L G C L V K D Y F P E P V T V S
TGGAACCTCAGGCGCCCTGACCAGCGGGGTGCACACCTTCCCGGTGTCTACAGTCCCTCA
W N S G A L T S G V H T F P A V L Q S S
GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACC
G L Y S L S S V V T V P S S L G T Q T
TACATCTGCAACGTGAATCACAAAGCCAGCAACACCAAGTGGACAAGAAAGTTGAGCCC
Y I C N V N H K P S N T K V D K K V E P
AAATCTTGTGACAAAACTCACACATGCCCCACCGTGCCCGCACCTGAACCTCCTGGGGGA
K S C D K T H T C P P C P A P E L L G G
CCGTACGTCTTCCCTCTTCCCCCAAAACCCAGGACACCCCTCATGATCTCCCGGACCCCT
P S V F L F P P K P K D T L M I S R T P
GAGGTCACATGCGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGG
E V T C V V V D V S H E D P E V K F N W

Figure 3A

SEQUENCE 44209001

TAGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGGGAGGAGCAGTACGCC
Y V D G V E V H N A K T K P R E E Q Y A 297
AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACAGGACTGGCTGAATGGCAAG
S T Y R V V S V L T V L H Q D W L N G K
GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAAACCATCTCC
E Y K C K V S N K A L P A P I E K T I S
AAAGCCAAAGGCGAGCCCCGAGAACACAGGTGTACACCCCTGCCCCCATCCCGGATGAG
K A K G Q P R E P Q V Y T L P P S R D E
CTGACCAAGAACCGGTTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATC
L T K N Q V S L T C L V K G F Y P S D I
GCCGTGGAGTGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCCCTCCCGTG
A V E W E S N G Q P E N N Y K T T P P V
CTGGACTCCGACGGCTCCTTCTCCTCTACAGCAAGCTCACCCGTGGACAAGAGCAGGTGG
L D S D G S F F L Y S K L T V D K S R W
CAGCAGGGGAACGTCTTCTCATGTCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
Q Q G N V F S C S V M H E A L H N H Y T
CAGAAAGAGCCTCTCCCTGTCTCCGGGTAATGA (SEQ ID NO:26)
Q K S L S L S P G K Op (SEQ ID NO:25)

Figure 3B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Theresa O'Keefe et al.
Serial No. : Unassigned
Filed : Herewith
Title : HYBRID ANTIBODIES AND USES THEREOF

BOX PATENT APPLICATION

Commissioner for Patents
Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I, Jennifer H. Payne, declare that I personally prepared the paper and the computer-readable copy of the Sequence Listing filed herewith for the above-identified application and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date:

January 30, 2002

Jennifer H. Payne

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
(617) 542-5070 telephone
(617) 542-8906 facsimile

20379167.doc

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 932 077 751 US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

January 30, 2002

Signature

Leroy Jenkins

Typed or Printed Name of Person Signing Certificate